TG Therapeutics, Inc. (NASDAQ:TGTX) Receives $40.67 Average Price Target from Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $40.67.

TGTX has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Finally, JPMorgan Chase & Co. upped their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th.

TG Therapeutics Trading Up 9.2 %

TGTX opened at $38.44 on Wednesday. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The company has a market cap of $6.04 billion, a price-to-earnings ratio of -384.36 and a beta of 2.30. The firm has a 50 day simple moving average of $31.07 and a 200 day simple moving average of $28.57. TG Therapeutics has a fifty-two week low of $12.93 and a fifty-two week high of $38.58.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, sell-side analysts anticipate that TG Therapeutics will post 0.08 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Vermillion Wealth Management Inc. bought a new position in TG Therapeutics during the 4th quarter worth approximately $30,000. Quadrant Capital Group LLC raised its holdings in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 975 shares during the last quarter. Blue Trust Inc. raised its holdings in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 371 shares during the last quarter. Smartleaf Asset Management LLC raised its holdings in TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,594 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,737 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.